Our overall aim is to understand the key processes in epithelial to mesenchymal transition (EMT) and metastasis, in order to identify targets for novel cancer therapies.
Our group focuses on an important signalling pathway involved in metastasis and EMT, the Wnt signalling pathway. We are particularly interested in investigating the epigenetic regulation of a number of key proteins involved in this pathway, and understanding their role in the context of ovarian, breast and colorectal cancer.
Prof William Rawlinson
Virology Research Laboratory, Prince of Wales Hospital
Dr Viola Heinzelmann-Schwarz, University Hospital, Basel, Switzerland
Prof Neville Hacker, Royal Hospital for Women
Grants & Funding
2013: Ovarian Cancer Research Foundation Grant - $140,000. Hear the Ror! A novel target in epithelial ovarian cancer.
2012: UNSW Faculty Research Grant - $20,000. The role of the Ror2 Wnt receptor tyrosine kinase in colorectal cancer
2011: Cure Cancer Australia Grant #1008633 - $90,000. Targeting the Wnt signalling pathway - a new metastatic and epigenetic therapy for ovarian cancer
2010-2012: NHMRC Project Grant #630458 - $318,750 . Wnt-5a signaling – a novel therapy for triple negative and Tamoxifen resistant breast cancer patients
2007-2011: NHMRC CJ Martin Fellowship #466005 - $314,589